Cited by 570Radiopharmaceutical Chemistry and ApplicationsRadioactivity and Radon MeasurementsMedical Imaging Techniques and Applications

The DOI matches its Crossref record; 363 of the 363 references it cites were found in a registry or an index.

MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy

Open access

Sgouros, George, Roeske, John C., McDevitt, Michael R., Palm, Stig, Allen, Barry J., Fisher, Darrell R., Brill, A. Bertrand, Song, Hong, Howell, Roger W., Akabani, Gamal·2010·Journal of Nuclear Medicine

DOI 10.2967/jnumed.108.058651PMC PMC5680544

Open this paper in CoChat — free account Open PDF

Abstract

The potential of alpha-particle emitters to treat cancer has been recognized since the early 1900s. Advances in the targeted delivery of radionuclides and radionuclide conjugation chemistry, and the increased availability of alpha-emitters appropriate for clinical use, have recently led to patient trials of radiopharmaceuticals labeled with alpha-particle emitters. Although alpha-emitters have been studied for many decades, their current use in humans for targeted therapy is an important milestone. The objective of this work is to review those aspects of the field that are pertinent to targeted alpha-particle emitter therapy and to provide guidance and recommendations for human alpha-particle emitter dosimetry.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2967/jnumed.108.058651

Cites

363 of 363 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

THE STOPPING AND RANGE OF IONS IN SOLIDS
Ziegler, J. F. (1988) · Elsevier eBooks · doi:10.1016/b978-0-12-780621-1.50005-8 · Cited by 9,077
THE STOPPING AND RANGE OF IONS IN SOLIDS
Ziegler, J. F. (1984) · Elsevier eBooks · doi:10.1016/b978-0-12-780620-4.50007-0 · Cited by 5,892
Recommendations of the International Commission on Radiological Protection
(1961) · Postgraduate Medical Journal · doi:10.1136/pgmj.37.425.168-b · Cited by 5,868
The Stopping and Range of Ions in Matter
Ziegler, J. F., & Biersack, J. P. (1985) · Springer eBooks · doi:10.1007/978-1-4615-8103-1_3 · Cited by 4,360
Radiobiology for the Radiologist.
(1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-80-3-438_1 · Cited by 3,498
The Stopping and Ranges of Ions in Matter
(1980) · Elsevier eBooks · doi:10.1016/c2013-0-02882-4 · Cited by 3,012
The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy
Thomlinson, R. H., & Gray, L. H. (1955) · British Journal of Cancer · doi:10.1038/bjc.1955.55 · Cited by 2,228
International Commission on Radiological Protection
(1969) · Radiology · doi:10.1148/93.6.1298 · Cited by 2,148
Basic anatomical and physiological data for use in radiological protection: reference values
Valentin, J. (2002) · Annals of the ICRP · doi:10.1016/s0146-6453(03)00002-2 · Cited by 2,024
Report of the task group on reference man
(1979) · Annals of the ICRP · doi:10.1016/0146-6453(79)90123-4 · Cited by 1,715

Show all 363 references

Research works printed but not linked: 32

2005, J Nucl Med., 46, 199S
1990, Antibody Immunoconjugates Radiopharm., 4, 85
1997, Blood., 90, 2245
2006, Cancer Biother Radiopharm., 21, 395
2006, Cancer Biother Radiopharm., 21, 396
2006, J Nucl Med., 47, 1049
International Commission on Radiological Protection. Relative Biological Effectiveness (RBE), Quality Factor (Q), and Radiation Weighting Factor (wR). Philadelphia, PA: Elsevier; 2004. ICRP publication 92.
1964, Cancer Res., 24, 683
1995, J Nucl Med., 36, 259
1989, Lancet., 2, 650
1997, J Nucl Med., 38, 727
2000, J Nucl Med., 41, 941
2007, Ann ICRP., 37, 1
1994, J Nucl Med., 35, 521
1993, J Nucl Med., 34, 1811
1988, Cancer Res., 48, 7022
1992, J Nucl Med., 33, 2167
1994, J Nucl Med., 35, 303
Fisher DR. The microdosimetry of monoclonal antibodies labeled with alpha emitters. In: Schlafke-Stelson AT, Watson EE, eds. Fourth International Radiopharmaceutical Dosimetry Symposium. Oak Ridge, TN: Oak Ridge Associated Universities; 1986:26–36.
Kellerer AM. Analysis of patterns of energy deposition: a survey of theoretical relations in microdosimetry. In: Ebert HG, ed. Proceedings of the Second Symposium on Microdosimetry. Brussels, Belgium: Commission of European Communities; 1970:107–134.
1997, J Nucl Med., 38, 1923
2004, J Nucl Med., 45, 129
2001, J Nucl Med., 42, 1216
1999, J Nucl Med., 40, 37S
1975, J Nucl Med., 16, 248
1999, J Nucl Med., 40, 1935
2002, J Nucl Med., 43, 97
2003, J Nucl Med., 44, 774
2005, J Nucl Med., 46, 1171
1969, J Nucl Med., 10, 7
1999, J Nucl Med., 40, 1947
Goodhead DT. Talk 23, Alpha Emitters, from Session 6, Effects from Specific Sources of Internal Radiation. Presented at: CERRIE Workshop; July 21–23, 2003; Oxford, U.K.

Sorted by citations

Items 201–300 of 570

Preclinical Evaluation of Podoplanin-Targeted Alpha-Radioimmunotherapy with the Novel Antibody NZ-16 for Malignant Mesothelioma
Sudo, H., Tsuji, A. B., Sugyo, A., Kaneko, M. K., Kato, Y., Nagatsu, K., Suzuki, H., & Higashi, T. (2021) · Cells · doi:10.3390/cells10102503 · Cited by 23
Alpha dose modeling in diffusing alpha‐emitters radiation therapy—Part I: single‐seed calculations in one and two dimensions
Heger, G., Roy, A., Dumančić, M., & Arazi, L. (2022) · Medical Physics · doi:10.1002/mp.16145 · Cited by 22
Efficacy of HER2-Targeted Intraperitoneal225Ac α-Pretargeted Radioimmunotherapy for Small-Volume Ovarian Peritoneal Carcinomatosis
Chung, S. K., Vargas, D. B., Chandler, C. S., Katugampola, S., Veach, D. R., McDevitt, M. R., Seo, S., Vaughn, B. A., Rinne, S. S., Punzalan, B. J., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.265095 · Cited by 22
Self-citation
A GATE simulation study for dosimetry in cancer cell and micrometastasis from the 225Ac decay chain
Koniar, H., Miller, C., Rahmim, A., Schaffer, P. C., & Uribe, C. (2023) · EJNMMI Physics · doi:10.1186/s40658-023-00564-5 · Cited by 22
Using α radiation to boost cancer immunity?
Gorin, J., Guilloux, Y., Morgenstern, A., Chérel, M., Davodeau, F., & Gaschet, J. (2014) · OncoImmunology · doi:10.4161/21624011.2014.954925 · Cited by 22
A Genomic Profile of Local Immunity in the Melanoma Microenvironment Following Treatment with α Particle-Emitting Ultrasmall Silica Nanoparticles
Urbanska, A. M., Khanin, R., Alidori, S., Wong, S., Mello, B. P., Almeida, B. A., Chen, F., Ma, K., Turker, M. Z., Korontsvit, T., et al. (2020) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2019.3150 · Cited by 22
Self-citation
Radiopharmaceutical therapy in the era of precision medicine
Sgouros, G., & Goldenberg, D. M. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.025 · Cited by 22
Self-citation
Dosimetry in molecular nuclear therapy
Wierts, R., de Pont, C. D. J. M., Brans, B. T., Mottaghy, F. M., & Kemerink, G. J. (2011) · Methods · doi:10.1016/j.ymeth.2011.09.016 · Cited by 22
Evaluation of 209 At as a theranostic isotope for 209 At-radiopharmaceutical development using high-energy SPECT
Crawford, J. R., Robertson, A. K. H., Yang, H., Rodríguez‐Rodríguez, C., Esquinas, P. L., Kunz, P., Blinder, S. A. L., Sossi, V., Schaffer, P. C., & Ruth, T. J. (2018) · Physics in Medicine and Biology · doi:10.1088/1361-6560/aaaa95 · Cited by 22
The five “W”s and “How” of Targeted Alpha Therapy: Why? Who? What? Where? When? and How?
Sollini, M., Marzo, K., Chiti, A., & Kirienko, M. (2020) · RENDICONTI LINCEI · doi:10.1007/s12210-020-00900-2 · Cited by 21
PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates
Veach, D. R., Storey, C. M., Lückerath, K., Braun, K., von Bodman, C., Lamminmäki, U., Kalidindi, T. M., Strand, S., Strand, J., Altai, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3614 · Cited by 21
Self-citation
A 211At-labelled mGluR1 inhibitor induces cancer senescence to elicit long-lasting anti-tumor efficacy
Xie, L., Zhang, L., Hu, K., Hanyu, M., Zhang, Y., Fujinaga, M., Minegishi, K., Ohkubo, T., Nagatsu, K., Jiang, C., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100960 · Cited by 21
Preclinical Investigation of [212Pb]Pb-DOTAM-GRPR1 for Peptide Receptor Radionuclide Therapy in a Prostate Tumor Model
Saidi, A., Stallons, T. A. R., Wong, A. G., & Torgue, J. J.-C. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268101 · Cited by 21
Microdosimetry and nanodosimetry for internal emitters
Li, W. B., HOFMANN, W., & Friedland, W. (2018) · Radiation Measurements · doi:10.1016/j.radmeas.2018.05.013 · Cited by 21
The potential of targeted radionuclide therapy to treat hypoxic tumor cells
Wenker, S. T. M., van Lith, S. A. M., Tamborino, G., Konijnenberg, M. W., Bussink, J., & Heskamp, S. (2024) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2024.108971 · Cited by 20
225 Ac/ 89 Zr-Labeled N4MU01 Radioimmunoconjugates as Theranostics Against Nectin-4–Positive Triple-Negative Breast Cancer
Babeker, H., Njotu, F. N., Ketchemen, J. P., Monzer, A., Tikum, A. F., Doroudi, A., Nwangele, E., Uppalapati, M., & Fonge, H. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268387 · Cited by 20
The effect of dimethyl sulfoxide on the induction of DNA strand breaks in plasmid DNA and colony formation of PC Cl3 mammalian cells by alpha-, beta-, and Auger electron emitters 223Ra, 188Re, and 99mTc
Runge, R., Oehme, L., Kotzerke, J., & Freudenberg, R. (2016) · EJNMMI Research · doi:10.1186/s13550-016-0203-x · Cited by 20
Uptake and subcellular distribution of radiolabeled polymersomes for radiotherapy
Roobol, S. J., Hartjes, T. A., Slotman, J. A., de Kruijff, R. M., Torrelo, G., Abraham, T. E., Bruchertseifer, F., Morgenstern, A., Kanaar, R., van Gent, D. C., et al. (2019) · Nanotheranostics · doi:10.7150/ntno.37080 · Cited by 20
Radioimmunotherapy with an 211At‐labeled anti–tissue factor antibody protected by sodium ascorbate
Takashima, H., Koga, Y., Manabe, S., Ohnuki, K., Tsumura, R., Anzai, T., Iwata, N., Wang, Y., Yokokita, T., Komori, Y., et al. (2021) · Cancer Science · doi:10.1111/cas.14857 · Cited by 20
A Physiologically Based Pharmacokinetic Model for In Vivo Alpha Particle Generators Targeting Neuroendocrine Tumors in Mice
Zaid, N. R. R., Kletting, P., Winter, G., Prasad, V., Beer, A. J., & Glatting, G. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122132 · Cited by 20
Diffusing alpha-emitters radiation therapy in combination with temozolomide or bevacizumab in human glioblastoma multiforme xenografts
Nishri, Y., Vatarescu, M., Luz, I., Epstein, L., Dumančić, M., Mare, S. D., Shai, A., Schmidt, M. T., Deutsch, L., Den, R. B., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.888100 · Cited by 20
Combination of Carriers with Complementary Intratumoral Microdistributions of Delivered α -Particles May Realize the Promise for 225 Ac in Large, Solid Tumors
Howe, A. K., Bhatavdekar, O., Salerno, D., Josefsson, A., Pacheco‐Torres, J., Bhujwalla, Z. M., Gabrielson, K. L., Sgouros, G., & Sofou, S. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262992 · Cited by 19
Self-citation
[212Pb]Pb-eSOMA-01: A Promising Radioligand for Targeted Alpha Therapy of Neuroendocrine Tumors
Chapeau, D., Koustoulidou, S., Handula, M., Beekman, S., de Ridder, C., Stuurman, D. C., de Blois, E., Buchatskaya, Y., van der Schilden, K., de Jong, M., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16070985 · Cited by 19
Beyond Average: α-Particle Distribution and Dose Heterogeneity in Bone Metastatic Prostate Cancer
Benabdallah, N., Lu, P., Abou, D. S., Zhang, H., Ulmert, D., Hobbs, R. F., Gay, H. A., Simons, B. W., Saeed, M. A., Rogers, B. E., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.266571 · Cited by 19
Correlation of the absorbed dose to the blood and DNA damage in leukocytes after internal ex-vivo irradiation of blood samples with Ra-224
Schumann, S., Eberlein, U., Müller, J., Scherthan, H., & Laßmann, M. (2018) · EJNMMI Research · doi:10.1186/s13550-018-0422-4 · Cited by 19
BIGDOSE: software for 3D personalized targeted radionuclide therapy dosimetry
Li, T., Zhu, L., Lu, Z., Song, N., Lin, K.-H., & Mok, G. S. P. (2019) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims.2019.10.09 · Cited by 19
Radiation dosimetry and efficacy of an 89Zr/225Ac-labeled humanized anti-MUC5AC antibody
Nakata, N., Kobashi, N., Okumura, Y., Sato, M., Matono, M., Otsuki, K., Tanaka, A., & Hayashi, A. (2022) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2022.02.003 · Cited by 19
Targeted alpha immunotherapy of CD20-positive B-cell lymphoma model: dosimetry estimate of 225Ac-DOTA-rituximab using 64Cu-DOTA-rituximab
Lee, C., Lim, I., Woo, S., Kim, W., Kim, K. I., Lee, K. C., Song, K., & Lim, S. M. (2021) · Annals of Nuclear Medicine · doi:10.1007/s12149-021-01607-6 · Cited by 18
A comparison of the chemo- and radiotoxicity of thorium and uranium at different enrichment grades
Rump, A. F., Hermann, C., Lamkowski, A., Popp, T., & Port, M. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03484-6 · Cited by 18
A third generation PSMA-targeted agent [211At]YF2: Synthesis and in vivo evaluation
Feng, Y., Meshaw, R. L., Finch, S. W., Zheng, Y., Minn, I., Vaidyanathan, G., Pomper, M. G., & Zalutsky, M. R. (2024) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2024.108916 · Cited by 18
Particle Beam Radiobiology Status and Challenges: A PTCOG Radiobiology Subcommittee Report
Ahmad, R., Barcellini, A., Baumann, K. S., Benje, M., Bender, T., Bragado, P., Charalampopoulou, A., Chowdhury, R., Davis, A. J., Ebner, D. K., et al. (2024) · International Journal of Particle Therapy · doi:10.1016/j.ijpt.2024.100626 · Cited by 18
Physics aspects of setting up a multicenter clinical trial involving internal dosimetry of radioiodine treatment of differentiated thyroid cancer
Taprogge, J., Leek, F. A. A., & Flux, G. (2019) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.19.03202-3 · Cited by 18
Biological and internal dosimetry for radiation medicine: current status and future perspectives
Sudprasert, W., Belyakov, O. V., & Tashiro, S. (2021) · Journal of Radiation Research · doi:10.1093/jrr/rrab119 · Cited by 18
ASTRO's Framework for Radiopharmaceutical Therapy Curriculum Development for Trainees
Kiess, A. P., Hobbs, R. F., Bednarz, B. P., Knox, S. J., Meredith, R. F., & Escorcia, F. E. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.03.018 · Cited by 18
A method to predict response of cell populations to cocktails of chemotherapeutics and radiopharmaceuticals: Validation with daunomycin, doxorubicin, and the alpha particle emitter 210Po
Akudugu, J., & Howell, R. W. (2012) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2012.01.011 · Cited by 18
Self-citation
Radionuclide-Labeled Biomaterials: A Novel Strategy for Tumor-Targeted Therapy
Zhang, S., Zhang, A., Qi, X., Han, Z., Song, L., Zhou, J., Wang, G., Zhu, R., & Li, J. (2025) · Biomimetics · doi:10.3390/biomimetics10060394 · Cited by 17
Impact of radiopharmaceutical therapy (177Lu, 225Ac) microdistribution in a cancer-associated fibroblasts model
Tranel, J., Palm, S., Graves, S. A., Feng, F. Y.-C., & Hope, T. A. (2022) · EJNMMI Physics · doi:10.1186/s40658-022-00497-5 · Cited by 17
Self-citation
Targeting Prostate Cancer Stem Cells with Alpha-Particle Therapy
Ceder, J. A., & Elgqvist, J. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2016.00273 · Cited by 17
The Role of Preclinical Models in Radiopharmaceutical Therapy
Sgouros, G., Hobbs, R. F., & Abou, D. S. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.e121 · Cited by 16
Self-citation
Comparison of Radionuclide Drug Conjugates With Boron Neutron Capture Therapy: An Overview of Targeted Charged Particle Radiation Therapy
Zhang, Y., Coghi, P. S., Ren, Z., Hosmane, N. S., & Zhu, Y. (2024) · Medicinal Research Reviews · doi:10.1002/med.22093 · Cited by 16
Review of current status of targeted alpha therapy in cancer treatment
Jabbar, T., Bashir, S., & Babar, M. (2023) · Nuclear Medicine Review · doi:10.5603/nmr.2023.0003 · Cited by 16
Future Treatment Strategies for Cancer Patients Combining Targeted Alpha Therapy with Pillars of Cancer Treatment: External Beam Radiation Therapy, Checkpoint Inhibition Immunotherapy, Cytostatic Chemotherapy, and Brachytherapy
Winter, R., Amghar, M., Wacker, A. S., Bakos, G., Taş, H., Roscher, M., Kelly, J. M., & Benešová, M. (2024) · Pharmaceuticals · doi:10.3390/ph17081031 · Cited by 16
Preclinical Comparison of [ 111 In]In- and [ 225 Ac]Ac-DOTA-Trastuzumab IgG, F(ab′) 2 and Fab for Theranostic SPECT/CT Imaging and α-Particle Radioimmunotherapy of HER2-Positive Human Breast Cancer
Kondo, M., Cai, Z., Chan, C., Brown, M. K., & Reilly, R. M. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c01071 · Cited by 16
Current landscape and future directions of targeted-alpha-therapy for glioblastoma treatment
Roncali, L., Hindré, F., Samarut, É., Lacœuille, F., Rousseau, A., D, J.-M. L. M., Garcion, E., & Chérel, M. (2025) · Theranostics · doi:10.7150/thno.106081 · Cited by 16
Internal Dosimetry
Li, W. B. (2018) · Japanese Journal of Health Physics · doi:10.5453/jhps.53.72 · Cited by 16
Radiation dosimetry in medicine using II-VI semiconductors
Damulira, E. (2022) · Journal of Radiation Research and Applied Sciences · doi:10.1016/j.jrras.2022.06.001 · Cited by 16
Response to RL‐225Ac in prostate cancer: Effect of prior treatment with RL‐177Lu: A systematic review of the literature
Stangl‐Kremser, J., Ricaurte‐Fajardo, A., Subramanian, K., Osborne, J. R., Sun, M., Tagawa, S. T., & Bander, N. H. (2023) · The Prostate · doi:10.1002/pros.24531 · Cited by 16
Innovation in Radionuclide Therapy for the Treatment of Prostate Cancers: Radiochemical Perspective and Recent Therapeutic Practices
Deshayes, E., Fersing, C., Thibault, C., Roumiguié, M., Pourquier, P., & Houédé, N. (2023) · Cancers · doi:10.3390/cancers15123133 · Cited by 16
Size-dependent therapeutic efficiency of 223 Ra-labeled calcium carbonate carriers for internal radionuclide therapy of breast cancer
Akhmetova, D. R., Mitusova, K. A., Postovalova, A. S., Ivkina, A. S., Muslimov, A. R., Zyuzin, M. V., Shipilovskikh, S. A., & Timin, A. S. (2023) · Biomaterials Science · doi:10.1039/d3bm01651j · Cited by 16
Radiopharmaceuticals Based on Alpha Emitters: Preparation, Properties, and Application
Garashchenko, B. L., Корсакова, В. А., & Yakovlev, R. Y. (2018) · Physics of Atomic Nuclei · doi:10.1134/s1063778818100071 · Cited by 16
Estimation of relative biological effectiveness of 225Ac compared to 177Lu during [225Ac]Ac-PSMA and [177Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS
Rumiantcev, M., Li, W. B., Lindner, S., Liubchenko, G., Resch, S., Bartenstein, P., Ziegler, S. I., Böning, G., & Delker, A. (2023) · EJNMMI Physics · doi:10.1186/s40658-023-00567-2 · Cited by 15
Approach to the Patient: Concept and Application of Targeted Radiotherapy in the Paraganglioma Patient
Pacák, K., Taïeb, D., Lin, F. I., & Jha, A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae252 · Cited by 15
Investigation of 209Bi (α,2n)211At reaction route for the production of α-emitter 211At
Özdoğan, H., Üncü, Y. A., Şekerci, M., & Kaplan, A. (2024) · The European Physical Journal Plus · doi:10.1140/epjp/s13360-024-05319-4 · Cited by 15
Mathematic Modeling of Tumor Growth During [ 177 Lu]Lu-PSMA Therapy: Insights into Treatment Optimization
Zaid, N. R. R., Bastiaannet, R., Hobbs, R. F., & Sgouros, G. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268457 · Cited by 15
Self-citation
Alpha particle spectroscopy using FNTD and SIM super‐resolution microscopy
Kouwenberg, J., Kremers, G., Slotman, J. A., Wolterbeek, H. T., Houtsmuller, A. B., Denkova, A. G., & Bos, A. J. J. (2018) · Journal of Microscopy · doi:10.1111/jmi.12686 · Cited by 15
Radiotoxicity of alpha particles versus high and low energy electrons in hypoxic cancer cells
Runge, R., Oehme, L., Kotzerke, J., Freudenberg, R., & Maucksch, U. (2018) · Nuklearmedizin - NuclearMedicine · doi:10.3413/nukmed-0950-17-12 · Cited by 15
Experimental Setups for In Vitro Studies on Radon Exposure in Mammalian Cells—A Critical Overview
Maier, A., Bailey, T., Hinrichs, A., Lerchl, S., Newman, R. T., Fournier, C., & Vandevoorde, C. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20095670 · Cited by 14
Complete Remissions of HER2-Positive Trastuzumab-Resistant Xenografts Using a Potent [225Ac]Ac-Labeled Anti-HER2 Antibody–Drug Radioconjugate
Ketchemen, J. P., Njotu, F. N., Babeker, H., Monzer, A., Nwangele, E., Tikum, A. F., Henning, N. W., Hassani, N., Frye, S. A., Perron, R., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1779 · Cited by 14
Advances With 225Ac-DOTATATE Targeted Alpha Therapy in Somatostatin Receptor Positive Neuroendocrine Tumors
Chandekar, K. R., & Bal, C. S. (2025) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2025.06.008 · Cited by 14
Differential gene expression in human fibroblasts after alpha-particle emitter211At compared with60Co irradiation
Danielsson, A., Claesson, K., Parris, T. Z., Helou, K., Nemes, S., Elmroth, K., Elgqvist, J., Jensen, H. J., & Hultborn, R. (2012) · International Journal of Radiation Biology · doi:10.3109/09553002.2013.746751 · Cited by 14
The effect of hypoxia on the induction of strand breaks in plasmid DNA by alpha-, beta- and Auger electron-emitters 223Ra, 188Re, 99mTc and DNA-binding 99mTc-labeled pyrene
Reissig, F., Wunderlich, G., Runge, R., Freudenberg, R., Lühr, A., & Kotzerke, J. (2020) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2020.01.003 · Cited by 14
TOPAS a tool to evaluate the impact of cell geometry and radionuclide on alpha particle therapy
Liberal, F. D. C. G., McMahon, S. J., & Prise, K. M. (2021) · Biomedical Physics & Engineering Express · doi:10.1088/2057-1976/abf29f · Cited by 14
The low‐LET radiation contribution to the tumor dose in diffusing alpha‐emitters radiation therapy
Epstein, L., Heger, G., Roy, A., Gannot, I., Kelson, I., & Arazi, L. (2023) · Medical Physics · doi:10.1002/mp.16885 · Cited by 14
Impact of α-Targeted Radiation Therapy on Gene Expression in a Pre-Clinical Model for Disseminated Peritoneal Disease when Combined with Paclitaxel
Yong, K. J., Milenic, D. E., Baidoo, K. E., & Brechbiel, M. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108511 · Cited by 14
An Analytical Microdosimetric Model for Radioimmunotherapeutic Alpha Emitters
Bertolet, A., Cortés-Giraldo, M. A., & Cárabe, A. (2020) · Radiation Research · doi:10.1667/rade-20-00045.1 · Cited by 14
Targeted Radium Alpha Therapy in the Era of Nanomedicine: In Vivo Results
Trencsényi, G., Csikos, C., & Képes, Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25010664 · Cited by 13
Development of a transmission alpha particle dosimetry technique using A549 cells and a Ra‐223 source for targeted alpha therapy
Darwish, R. A., Staudacher, A. H., Li, Y., Brown, M. P., & Bezak, E. (2016) · Medical Physics · doi:10.1118/1.4965805 · Cited by 13
Two diverse carriers are better than one: A case study in α‐particle therapy for prostate specific membrane antigen‐expressing prostate cancers
Salerno, D., Howe, A. K., Bhatavdekar, O., Josefsson, A., Pacheco‐Torres, J., Bhujwalla, Z. M., Gabrielson, K. L., & Sofou, S. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10266 · Cited by 13
Intra-Arterial Delivery of Radiopharmaceuticals in Oncology: Current Trends and the Future of Alpha-Particle Therapeutics
Kauffman, N., Morrison, J., O’Brien, K., Fan, J., & Zinn, K. R. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041138 · Cited by 13
Tumor Control Probability and Small-Scale Monte Carlo Dosimetry: Effects of Heterogenous Intratumoral Activity Distribution in Radiopharmaceutical Therapy
Mellhammar, E., Dahlbom, M. L., Timmermand, O. V., & Strand, S. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265523 · Cited by 13
Biodistribution of 212Pb conjugated trastuzumab in mice
Schneider, N. R., Lobaugh, M., Tan, Z., Sandwall, P. A., Chen, P., Glover, S. E., Cui, L., Murry, M. M., Dong, Z., Torgue, J. J.-C., et al. (2012) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-012-2243-7 · Cited by 13
Alpha Particles Induce Autophagy in Multiple Myeloma Cells
Gorin, J., Gouard, S., Ménager, J., Morgenstern, A., Bruchertseifer, F., Faivre-Chauvet, A., Guilloux, Y., Chérel, M., Davodeau, F., & Gaschet, J. (2015) · Frontiers in Medicine · doi:10.3389/fmed.2015.00074 · Cited by 13
Cancer Cell Radiobiological Studies Using In-House-Developed α-Particle Irradiator
Nilsson, J., Bauden, M. P., Nilsson, J. M. C., Strand, S., & Elgqvist, J. (2015) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2015.1895 · Cited by 13
Relationship between Size and Function of Natural Substance Particles
Zhang, Y. (2011) · Nano Biomedicine and Engineering · doi:10.5101/nbe.v3i1.p1-16 · Cited by 13
Targeted Radionuclide Therapy
Meredith, R. F., Wong, J. Y. C., & Knox, S. J. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1637-5.00022-5 · Cited by 13
Potent candidates for Targeted Alpha Therapy (TAT)
Filosofov, D. V., Baimukhanova, A., Khushvaktov, J., Kurakina, E. S., & Radchenko, V. (2025) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2025.109027 · Cited by 12
225 Ac α-Pretargeted Radioimmunotherapy of Human Epidermal Growth Factor Receptor 2–Expressing Breast Cancer
Rinne, S. S., Vargas, D. B., Seo, S., Veach, D. R., McDevitt, M. R., Vaughn, B. A., Xu, H., Guo, H.-F., Fung, E. K., de Stanchina, E., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.269601 · Cited by 12
Self-citation
Radiobiological effect of alpha particles. The scientific basis of targeted alpha-particle therapy
Cruz-Nova, P., Trujillo-Nolasco, M., Aranda‐Lara, L., Ferro‐Flores, G., & Ocampo-García, B. (2025) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2025.109044 · Cited by 12
Actinium-225/Bismuth-213 as Potential Leaders for Targeted Alpha Therapy: Current Supply, Application Barriers, and Future Prospects
Nawar, M. F., Selim, A. A., Essa, B. M., El-Daoushy, A. F., Swidan, M. M., Chambers, C., Al-Qahtani, M. H., Smith, C. J., & Sakr, T. M. (2025) · Cancers · doi:10.3390/cancers17183055 · Cited by 12
Covalent core-radiolabeling of polymeric micelles with 125I/211At for theranostic radiotherapy
Sporer, E., Poulie, C. B. M., Bäck, T. A., Lindegren, S., Jensen, H. J., Kempen, P. J., Kjær, A., Herth, M. M., & Jensen, A. I. (2022) · Nanotheranostics · doi:10.7150/ntno.71906 · Cited by 12
A cell-based dosimetry model for radium-223 dichloride therapy using bone micro-CT images and GATE simulations
Pinto, G. M., Bonifácio, D. A. B., de Sá, L. V., Lima, L. F. C., Vieira, I. F., & Lopes, R. T. (2020) · Physics in Medicine and Biology · doi:10.1088/1361-6560/ab6b42 · Cited by 12
The role of dosimetry and biological effects in metastatic castration–resistant prostate cancer (mCRPC) patients treated with 223Ra: first in human study
Sciuto, R., Rea, S., Ungania, S., Testa, A., Dini, V., Tabocchini, M. A., Patrono, C., Soriani, A., Palma, V., Marconi, R., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02056-9 · Cited by 12
Radio-immunothérapie alpha
Ménager, J., Gorin, J., Fichou, N., Gouard, S., Morgenstern, A., Bruchertseifer, F., Davodeau, F., Kraeber‐Bodéré, F., Chérel, M., Gaschet, J., et al. (2016) · médecine/sciences · doi:10.1051/medsci/20163204014 · Cited by 12
Emerging Therapeutic Radiopharmaceuticals and Their Theranostic Pairs
Carbo‐Bague, I., & Ramogida, C. F. (2021) · Wiley eBooks · doi:10.1002/9781119951438.eibc2763 · Cited by 12
Cure of Disseminated Human Lymphoma with [225Ac]Ac-Ofatumumab in a Preclinical Model
Longtine, M. S., Shim, K., Hoegger, M. J., Benabdallah, N., Abou, D. S., Thorek, D. L. J., & Wahl, R. L. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.265167 · Cited by 11
Effective therapy with Bismuth-212 labeled macroaggregated albumin in orthotopic mouse breast tumor models
Kauffman, N., Singh, S. K., Morrison, J., & Zinn, K. R. (2023) · Frontiers in Chemistry · doi:10.3389/fchem.2023.1204872 · Cited by 11
Evaluation of targeting αVβ3 in breast cancers using RGD peptide-based agents
Josefsson, A., Cortez, A. G., Yu, J., Majumdar, S., Bhise, A., Hobbs, R. F., & Nedrow, J. R. (2024) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2024.108880 · Cited by 11
B7-H3-targeted Radioimmunotherapy of Human Cancer
Kasten, B. B., Ferrone, S., Zinn, K. R., & Buchsbaum, D. J. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190228120908 · Cited by 11
Anti-Tumor Efficacy of PD-L1 Targeted Alpha-Particle Therapy in a Human Melanoma Xenograft Model
Capitao, M., Perrin, J., Simon, S., Gouard, S., Chouin, N., Bruchertseifer, F., Morgenstern, A., Rbah‐Vidal, L., Chérel, M., Scotet, E., et al. (2021) · Cancers · doi:10.3390/cancers13061256 · Cited by 11
Combination of Antiretroviral Drugs and Radioimmunotherapy Specifically Kills Infected Cells from HIV-Infected Individuals
Tsukrov, D. I., McFarren, A., Morgenstern, A., Bruchertseifer, F., Dolce, E., Górny, M. K., Zolla‐Pazner, S., Berman, J. W., Schoenbaum, E. E., Zingman, B. S., et al. (2016) · Frontiers in Medicine · doi:10.3389/fmed.2016.00041 · Cited by 11
Mechanistic Modeling of Radium-223 Treatment of Bone Metastases
Moreira, H., Liberal, F. D. C. G., O’Sullivan, J. M., McMahon, S. J., & Prise, K. M. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.12.015 · Cited by 11
Radionuclide spatial distribution and dose deposition for in vitro assessments of 212Pb‐αVCAM‐1 targeted alpha therapy
Frelin-Labalme, A.-M., Roger, T., Falzone, N., Lee, B. Q., Sibson, N. R., Vallis, K. A., Bernaudin, M., Valable, S., & Corroyer‐Dulmont, A. (2019) · Medical Physics · doi:10.1002/mp.13969 · Cited by 11
Establishment of a practical methodology for evaluating equieffective dose of individual patients based on RT-PHITS
Sato, T., Furuta, T., Sasaki, H., & Watabe, T. (2025) · EJNMMI Physics · doi:10.1186/s40658-025-00743-6 · Cited by 10
Recommendations on the Clinical Application and Future Potential of α-Particle Therapy: A Comprehensive Review of the Results from the SECURE Project
Iorio, V. D., Sarnelli, A., Boschi, S., Sansovini, M., Genovese, R. M., Ştefănescu, C., Ghizdovăţ, V., Jalloul, W., Young, J. D., Sosabowski, J. K., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18101578 · Cited by 10
Efficacy of a HER2-Targeted Thorium-227 Conjugate in a HER2-Positive Breast Cancer Bone Metastasis Model
Karlsson, J., Hagemann, U. B., Cruciani, V., Schatz, C. A., Grant, D., Ellingsen, C., Kristian, A., Katoozi, S., Mihaylova, D., Uran, S. R., et al. (2023) · Cancers · doi:10.3390/cancers15133419 · Cited by 10
First measurements of radon‐220 diffusion in mice tumors, towards treatment planning in diffusing alpha‐emitters radiation therapy
Heger, G., Dumančić, M., Luz, I., Vatarescu, M., Weizman, N., Miller, B. W., Cooks, T., & Arazi, L. (2024) · Medical Physics · doi:10.1002/mp.17020 · Cited by 10
Antigen targeting and anti-tumor activity of a novel anti-CD146 212Pb internalizing alpha-radioimmunoconjugate against malignant peritoneal mesothelioma
Lindland, K., Malenge, M. M., Li, R. G., Wouters, R., Bønsdorff, T. B., Juzeniene, A., & Dragovic, S. M. (2024) · Scientific Reports · doi:10.1038/s41598-024-76778-z · Cited by 10
Transitional Epithelium of Urinary Bladder: Dosimetric Data for Cells at Risk in Nuclear Medicine
Eckerman, K. F., & Veinot, K. G. (2018) · IEEE Transactions on Radiation and Plasma Medical Sciences · doi:10.1109/trpms.2018.2816303 · Cited by 10
Radioimmunotherapy for Brain Metastases: The Potential for Inflammation as a Target of Choice
Corroyer‐Dulmont, A., Jaudet, C., Frelin-Labalme, A.-M., Fantin, J., Weyts, K., Vallis, K. A., Falzone, N., Sibson, N. R., Chérel, M., Kraeber‐Bodéré, F., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.714514 · Cited by 10
Immunotherapy for melanoma
Lacy, K. E., Karagiannis, S. N., & Nestle, F. O. (2012) · Expert Review of Dermatology · doi:10.1586/edm.11.80 · Cited by 10

Authors: Sgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., Brill, A. B., Song, H., Howell, R. W., & Akabani, G.
Affiliations: Johns Hopkins University (US)
Loyola University Medical Center (US)
Memorial Sloan Kettering Cancer Center (US)
International Atomic Energy Agency (AT)
Pacific Northwest National Laboratory (US)
Vanderbilt University (US)
Rutgers, The State University of New Jersey (US)
Texas A&M University (US)
ORCID: Roeske, John C.
McDevitt, Michael R.
Palm, Stig
Fisher, Darrell R.
Brill, A. Bertrand
Howell, Roger W.
Akabani, Gamal
Venue: Journal of Nuclear Medicine
Publisher: Society of Nuclear Medicine
Published: 2010-01-15
Volume: 51
Issue: 2
Pages: 311-328
ISSN: 0161-5505 (ISSN-L)
2159-662X
DOI: 10.2967/jnumed.108.058651
PMC: PMC5680544
OpenAlex: W2018649196
Cited by: 552
References: 363
Citations by year: 2026: 60 · 2025: 58 · 2024: 50 · 2023: 54 · 2022: 50 · 2021: 50 · 2020: 39 · 2019: 34 · 2018: 44 · 2017: 17 · 2016: 21 · 2015: 10 · 2014: 25 · 2013: 11 · 2012: 16
FWCI: 9.79
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Nuclear Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute on Aging (P50AG005136)
National Cancer Institute (R01CA109234, R41CA117599, P30CA008748)
National Institute of Biomedical Imaging and Bioengineering (R01EB001994)
National Center for Research Resources (R43RR015155)
Topics: Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
Physical Sciences › Physics and Astronomy › Radiation › Radioactivity and Radon Measurements
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords: alpha-emitting radionuclides, targeted alpha therapy, radiation biology, dosimetry, radionuclide conjugation, radiopharmaceuticals, cancer therapy
MeSH terms: Alpha Particles, Cell Survival, Clinical Trials as Topic, Dose-Response Relationship, Radiation, Female, Humans, Male, Neoplasms, Neoplasms, Radiation-Induced, Pamphlets, Radiation-Protective Agents, Radiobiology, Radioisotopes, Radiotherapy Dosage, Radiotherapy Planning, Computer-Assisted, Relative Biological Effectiveness, Societies, Medical, Cell Death

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks